We assayed glucose tolerance and insulin secretion in ten patients with metastatic carcinoid tumors and the carcinoid syndrome (“active tumors”) and in seven patients with metastatic carcinoid tumors without the carcinoid syndrome (“inactive tumors”). The patients with “active tumors” had elevated serum serotonin levels while the patients with “inactive tumors” had normal serum serotonin levels. Of the ten patients with “active tumors”, five had diabetic and three had borderline intravenous glucose disposal rate constants (KG = 0.88 ± 0.07, M. ± S.E.M.). Their KG was significantly lower (p<0.01) than a group of agematched normals. AH of the patients with “inactive tumors” had normal KG values (KG = 1.67 ± 0.24). Their KG did not differ from that of age-matched normal subjects. Both groups of carcinoid patients had a comparable decrease in their insulinogenic index. Two days' administration of the serotonin antagonist cyproheptadine (Cypro) to eight of the patients with “active tumors” resulted in a significant increase in the “insulinogenic index” (50 per cent) but a nonsignificant increase in the KG (12 per cent). Administration of p-chlorophenylalanine, a compound that blocks serotonin synthesis, resulted in an increase in both the KG (60 per cent) and the “insulinogenic index” (55 per cent). The insulin half-life (½) of patients with “active tumors” (6.1 ± 0.4 min.) did not differ from the t½ of normal subjects (6.6 ± 0.4 min.), suggesting that the decreased plasma insulin levels following intravenous glucose were due to impaired insulin secretion rather than accelerated insulin destruction. Seven of the patients received treatment with the antitumor agent streptozotocin (Strepto). The patients received cumulative doses of from 70 to 300 mg. of Strepto per kilogram body weight with no impairment in glucose tolerance or insulin secretion. We conclude that there is high incidence of glucose intolerance (80 per cent) and impaired insulin secretion in patients with the carcinoid syndrome and that serotonin plays a role in producing these alterations.
Skip Nav Destination
Original contribution| July 01 1975
Glucose Intolerance in the Carcinoid Syndrome
Jerome M Feldman, MD;
James W Plonk, MD;
Carl H Bivens, MD;
Address reprint requests to Jerome M. Feldman, M.D., Box 2963, Duke University Medical Center, Durham, North Carolina 27710.
Jerome M Feldman, James W Plonk, Carl H Bivens, Harold E Lebovitz; Glucose Intolerance in the Carcinoid Syndrome. Diabetes 1 July 1975; 24 (7): 664–671. https://doi.org/10.2337/diab.24.7.664
Download citation file: